Private Eyes Awarded Background Check Services Agreement with Premier

WALNUT CREEK, Calif. (PRWEB) December 18, 2017

Private Eyes has been awarded a group purchasing agreement for Background Checks with Premier. Effective March 1, 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Background Checks Services.

“We are excited to continue our long-term relationship with Premier,” says Sandra James, CEO of Private Eyes. “We are grateful that since 2006, with Premier’s support, we have grown our market share in healthcare.”

Private Eyes, Inc.'s core business is focused on providing superior background checks. In order to meet the varying needs of their client base, they offer a variety of screening services including pre and post-employment screening, license, employment and educations verifications, drug screening and monthly monitoring.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Private Eyes:

Private Eyes is the leading protector of businesses in America by uniquely verifying their associates fast. Since 1999, the staff at Private Eyes has committed themselves to providing the best pre-employment screening for businesses seeking to reduce their liability risk in their hiring procedures. For more information, visit http://www.privateeyesbackgroundchecks.com.

Read the full story at http://www.prweb.com/releases/2017/12/prweb15019398.htm

Enterprise Implementation of Clinical Trial Technology Dominates Discussion at the 2017 DrugDev Summit, Co-Chaired by Novartis and CSL Behring

PHILADELPHIA and LONDON (PRWEB) December 18, 2017

Enterprise implementation of clinical technology solutions was easily the most discussed theme at the 2017 DrugDev Summit, co-chaired by Novartis and CSL Behring last month in Philadelphia. More than 125 of the industry’s most forward-thinking executives from approximately 50 sponsors and sites gathered for two days to share their experiences using the DrugDev Spark™ clinical operations suite, highlighted by case studies, best practices, challenges and hopes for the future.

The event featured inspirational keynotes, hands-on product workshops, engaging deep-dive discussions on hot-button clinical trial issues, and first looks at new and upcoming DrugDev Spark solutions. Presentations were delivered by companies including Allergan, Alnylam Pharmaceuticals, Amgen, Bayer, Boehringer-Ingelheim, CSL Behring, Janssen, Karyopharm Therapeutics, Meridien Research, Novartis, and Roche, along with several site representatives.

Some of the more popular topics included…

  • The business case for enterprise implementations of the DrugDev Spark clinical operations suite at three Top 10 pharmaceutical companies
  • How one company integrated systems and processes to achieve transformational change and unlock the power of clinical researchers worldwide
  • Dispelling myths of electronic informed patient consent (eConsent), and why it is rapidly increasing in adoption around the world
  • The DrugDev Spark roadmap and how it drives IQVIA clinical technology
  • How shared data sources and cross-company collaboration enables informed site selection decisions
  • Why site payments represent the most boring (and important) success factor for sites
  • How the unified integrated site activation and engagement solutions on DrugDev Spark helped one sponsor beat its enrollment timelines and goals

Attendees also were riveted by a keynote from Daniel DeFabio and Bo Bigelow, producers of “Disorder: The Rare Disease Film Festival.” The pair of passionate and committed rare disease advocates shared their personal stories and how they created a film movement and event that drew hundreds of researchers and patients to Boston in October. Currently they are seeking to capture, collect and curate at least one film for every rare disease currently identified as part of their “7,000 Films Wanted” initiative. To learn more, visit https://www.rarediseasefilmfestival.com/7000-films-wanted

From the educational sessions and thought-provoking deep dives to the social networking opportunities and hands-on DrugDev Spark product workshops, feedback from attendees was overwhelmingly positive. Comments from a post-event feedback survey included…

“The DrugDev Summit was a great experience! I enjoyed meeting folks from DrugDev, and enjoyed learning about enterprise solutions. It was extremely informative, and fun too.” – Patrick Lynch, Site Payments Manager, Karyopharm Therapeutics

“It was great. I learned a lot and am excited to share my learnings with the rest of my department. I think there's a lot for us to think about in terms of how DrugDev Spark can make everything easier and more efficient.” – Lauren Alves, Senior Clinical Trial Manager, Alnylam Pharmaceuticals

“As a site, the DrugDev Summit was a great opportunity for my organization to provide practical feedback about clinical trial technology application and value, while gaining insight about how sponsors and CROs make decisions regarding the use of such technology. I was honored to be invited and to share my perspective.” – Kelly Toms, Business Development Manager, Meridien Research

Added Kristopher Sarajian, DrugDev Vice President of Marketing, “The DrugDev Summit is the highlight of our year – where else can we have such a dedicated and exclusive opportunity to meet and socialize with over 125 customers who are leading the ongoing change movement in clinical research? I’m still amazed that it continues to grow larger than many industry conferences, and I’m honored so many people find our Summit to be such a productive use of their time. It’s a testament not only to the personal relationships DrugDev maintains with its customers, but also to the value of the presentations, open discussions and unfiltered feedback led by attendees. Each year, the Summit gets better and better because customers and sites continue to share their results of their innovative use of technology like DrugDev Spark, and I can’t wait to see what they accomplish next.”

About DrugDev

DrugDev, an IQVIA company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.

Read the full story at http://www.prweb.com/releases/2017/12/prweb15012944.htm

PENETRON ADMIX: Sure Solution for Hostile Coastal Site

East Setauket, New York (PRWEB) December 18, 2017

When confronted with a complex construction project on an oceanfront site that was completed December 2017, a South African builder opted for PENETRON ADMIX to ensure a durable – and impermeable – underground concrete structure. The crystalline admixture becomes an integral part of the matrix for the life of the concrete.

“The building project, now the KwaZulu-Natal branch office of EY (formerly Ernst & Young), was developed specifically to meet the requirements of EY by the owners, the United African Marine Insurance Company,” explains Clive Leader, Managing Director of PENETRON South Africa. “The project encompassed two phases of construction to add a new garage and expand the existing below-ground structure.”

Adding a two-floor underground parking garage to an existing building is a complex undertaking that demands precise planning, substantial construction expertise and – because of the marine environment in this part of South Africa – an absolutely reliable waterproofing solution.

As defined by the American Concrete Institute (ACI), permeability-reducing concrete admixtures (PRAHs) can provide comprehensive protection against concrete deterioration caused by chemical attack and corrosion from chloride penetration (i.e. seawater), even under high hydrostatic pressure.

As a recognized PRAH, the PENETRON ADMIX crystalline admixture can significantly increase concrete durability and service life. The active ingredients in PENETRON ADMIX form a catalytic reaction with moisture in fresh concrete to generate a permanent crystalline formation throughout the concrete. These crystals permanently seal microcracks, pores and capillaries in the concrete matrix against the penetration of water or liquids from any direction, even under hostile environmental conditions.

Easily mixed in during batching and unaffected by climatic conditions, PENETRON ADMIX was added to just over 400 m3 of the concrete mix to become an integral part of the concrete matrix; it also enhances the compressive strength of concrete and provides ‘self-healing’ capabilities for cracks during the life of the concrete.

“Thanks to a successful and productive relationship with Rubro Building Contractors, where PENETRON products were successfully applied to a number of challenging situations, PENETRON ADMIX was specified to treat the concrete for this project in KwaZulu-Natal,” adds Mr. Leader.

The PENETRON Group is a leading manufacturer of specialty construction products for concrete waterproofing, concrete repairs and floor preparation systems. The Group operates through a global network, offering support to the design and construction community through its regional offices, representatives and distribution channels.

For more information on PENETRON waterproofing solutions, please visit penetron(dot)com or Facebook(dot)com/ThePenetronGroup, email CRDept(at)penetron(dot)com, or contact the Corporate Relations Department at 631-941-9700.

Read the full story at http://www.prweb.com/releases/Penetron/ParkingGarage/prweb14676910.htm